

C-Path Names Colin Hill to Board of Directors

TUCSON, Ariz., Sept. 30, 2025 — Critical Path Institute® (C-Path) today announced the election of Colin Hill, M.S., to its Board of Directors. Hill brings deep experience at the intersection of artificial intelligence, drug development, and translational acceleration. The appointment will further strengthen C-Path’s Board of Directors’ commitment to provide optimal strategic support to the organization’s growth in advancing drug development through collaboration.

Hill is chief executive officer and co-founder of Aitia, a company advancing precision medicine through artificial intelligence. He currently serves on the board of Fulcrum Therapeutics (NASDAQ:FULC), a rare genetic disease small molecule company with a new drug candidate for sickle cell anemia in clinical development, and Centrexion Therapeutics, a biotech company developing non-opioid, non-addictive chronic-pain medicines. Hill has also served recently on the boards of BioTelemetry Inc. (acquired by Royal Philips) and PPD Inc. (acquired by Thermo Fisher Scientific) and was a founding director of AesRx (acquired by Baxter International). He co-founded Transforming Medicine: The Elizabeth Kauffman Institute, sat on the Massachusetts Digital Health Council, chaired O’Reilly Media’s first healthcare big-data conference, and was named to MIT Technology Review’s TR100 list. Hill earned a degree in physics from Virginia Tech and master’s degrees in physics from McGill University and Cornell University.



Colin Hill

“Colin has a record of turning complex data into decisions teams can act on,” said Wainwright Fishburn, chairman of the board at C-Path. “He understands how to build companies and tools that support the hard choices in development, and that experience will serve our mission.”

“C-Path depends on models and datasets that stand up to scientific and regulatory scrutiny,” said C-Path CEO Klaus Romero, M.D., M.S., FCP. “Colin brings key strategic insights for our core competencies, which benefit developers, regulators, and those with lived experiences.”

“My entire career – including our work at Aitia – has been dedicated to building a deep understanding of complex disease biology as the best approach to effective drug discovery and development,” said Hill. “I am honored to bring that focus to the C-Path Board of Directors to help them in their mission to bring together all the platforms, data, and stakeholders needed to fully realize the promise of precision medicine.”

The appointment takes effect immediately.

About Critical Path Institute

Founded in 2005, as a public-private partnership in response to the [FDA’s Critical Path Initiative](#), Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and

initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

Media Contacts:

Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org

Kissy Black
C-Path
615.310.1894
kblack@c-path.org